Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03126591
Title A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Eli Lilly and Company
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | FRA | DNK | BEL

Facility Status City State Zip Country Details
Dana Farber Cancer Institute Boston Massachusetts 02115 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15232 United States Details
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg Leuven 3000 Belgium Details
Herlev and Gentofte Hospital Herlev 2730 Denmark Details
Gustave Roussy Villejuif Cedex 94805 France Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field